Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has reported positive interim and preliminary results from its Phase 1/2 study of NT219, a first-in-class dual inhibitor of IRS 1/2 and STAT3. The company is planning the next clinical development steps with NT219 for second-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head & neck.
October 03, 2023 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Positive results from Purple Biotech's Phase 1/2 study of NT219 could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that Purple Biotech's NT219 has shown promising results, this could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100